STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million

STAT PlusExclusive CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million In a competitive field, executives express confidence they will win the ‘foot race’ Manage alerts for this article Email this article Share this article By Allison DeAngelisMay 14, 2026 Biotech Startups and Venture Capital Reporter Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.

Up until last year, CREATE was known as Myeloid Therapeutics. The startup was cofounded by noted writer and oncologist Siddhartha Mukherjee to develop better CAR-T therapies using a type of immune agent called myeloid cells, ideally to better attack solid tumors. The company rebranded last fall and, like many other oncology CAR-T companies, expanded into autoimmune disease research.

Advertisement Now, CREATE has raised another $122 million from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners, and others, the biotech told STAT exclusively. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.

STAT+ Newsletter Senior writer Adam Feuerstein's unfiltered, uncompromising analysis on the biotech world Recommended Biotech May 14, 2026 STAT Plus: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission Adam's Biotech Scorecard May 14, 2026 STAT Plus: ‘No drama’ Diamantas should serve biotech well as acting FDA chief Advertisement Exclusive May 13, 2026 STAT Plus: What the Trump administration wants in its next FDA leader The Readout May 13, 2026 STAT Plus: Gene therapy viruses linked to a boy’s tumor Biotech May 13, 2026 STAT Plus: Drug meant to make gene therapy safer may also make it less effective Subscriber Picks